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Introduction 
I.INTRODUCTION 
I.l.ATHEROSCLEROSIS 
Atherosclerosis is a progressive disease of the arterial blood vessel wall. It is 
most often clinicaly manifested as myocardial and cerebral infarction or as ischemic 
heart disease but also other parts of the circulatory systém could be affected. Many 
processes have been implicated including shear stress-related events, local adherence 
of platelets, lipoprotein oxidation and aggreration, macrophage chemotaxis, smooth 
muscle cell alterations and foam cell formation. 
1.1.1.ATHEROSCLEROTIC LESIONS 
Three main forms and stages at the same time of atherosclerotic lesions are 
distinguished: fatty streaks, fibrous and atheroma plaques, and complex advanced 
lesions (Češka, 1999). 
There are several hypothesis concerning the atherosclerotic lesions 
development. The response to injury hypothesis assumed that an injury to the 
endothelium might precipitate the atherosclerotic process. It is based on 
manifestations of the endothelium dysfunction caused by injury notably at branch 
points in the arterial tree. Increased lipoprotein plasma levels and their enhanced 
modification and entry in the vessel intima is the key process for the response to lipid 
infiltration hypothesis. On the contrary the response to retention hypothesis of early 
atheogenesis consider not the accelerated infiltration of lipoproteins but the enhanced 
retention of modified lipoproteins in the intima of blood vessel as the initial cause of 
lesion formation (Ross,1993; Augé el al., 1996; Inoue et <j/.,2001). 
1.1.2.ATHEROSCLEROSIS RISK FACTORS 
Several studies have proposed that abnormal lipids, smoking, hypertension, 
diabetes, abdominal obesity, high cholesterol diet and low physical activity account 
for most of the risk of premature atherosclerosis dvelopment (Maas a Boger,2003; 
Yusuf etal.,2004). Besides age, male sex and genetic predisposition are the non 
modifiable risk factors. Elevated sérum lipids are caused by disruption of lipoproteins 
structure and metabolism. The basic lipoprotein particles are chylomicrons, VLDL 
(Very Low Density Lipoprotein), IDL (Intermediate Density Lipoprotein), LDL 
(Low Density Lipoprotein), and HDL (High Density Lipoprotein). Lipoprotein(a), 
Lp(a), is the unique human plasma lipoprotein. 
I.2.LIPOPROTEIN(a) 
Lipoprotein(a), Lp(a), is a cholesterol-rich particle that is now recognized to 
be an independent risk factor for development of atherosclerosis (Djurovic et 
a/., 1997; Luc et a/.,2002; Emanuele et a/.,2004). Lipoprotein(a) consists of LDL 
particle covalently bound to a specific glycoprotein, apolipoprotein(a), apo(a). By 
sequencing cloned human apo(a) cDNA, McLean et al. (1987) showed that apo(a) is 
very similar to human plasminogen. It is likely that the LPA gene arose from a 
duplication of the plasminogen gene, perhaps recently during mammalian evolution. 
Studies have demonstrated that Lp(a) plasma concentrations are highly 
heritable and determined primarily by the gene for apo(a), so called LPA locus 
(Austin et al., 1992; de Meester et al., 1995). 
1.2.1.LPA L O C U S 
1.2.1.1 .LPA locus structure 
The size of apo(a) is highly variable ranging from 300 to 800 kDa (White et 
al., 1994). Apolipoprotein(a) is coded at LPA locus (GeneID:4018) that resides the 
6q26-q27 chromosomal region. It contains a serin protease domain, which cannot be 
activated by tissue plasminogen activator (t-PA). Apolipoprotein(a) as well as 
plasminogen consists of tandemly arrayed kringle motifs (K). There are five different 
kringles, KI-KV, in the plasminogen sequence and only two different kringles. 
KlpaIV and KLPAV, in the apo(a) protein. However apo(a) is much Iarger than 
plasminogen due to multiple copies of the KLPAIV motif (type 1-10) that are 75-85% 
homologous to that of plasminogen. Moreover, while KLPAIV typel and type 3-10 are 
present as a single copy KlpaIV type 2 occurs in a variable number of tandem repeats 
(Lackner et al., 1991; Guevara et al., 1993). 
Variation in the number of the kringlelV type 2 motifs explains the 
genetically determined size polymorphism of apo(a) that is inversely correlated with 
plasma Lp(a) levels (Holmer et al.,2003). 
1.2.1.2.Sequence variability in LPA locus 
There is still a large variation in Lp(a) levels among carriers of a certain 
apo(a) length isoform (Cohen etal., 1993). It has been revealed that the abundance of 
apo(a) mRNA transcripts of the same size can vary greatly between individuals 
(Wade et al., 1991), proposing that some of the variation in Lp(a) concentrations can 
be related to differences in the rate of LPA gene transcription. Besides sequence 
variants from LPA gene coding regions can affect Lp(a) particle production rate. 
1.2.1.2.1. Transcription control regions 
1.2.1.2.1.1. Promotér 
The so called minimal promotér (from -98 bp to + 141 bp upstream from the 
transcription start site) consists of transcription elements that are able to ensure the 
basal transcription activity (Wade et al., 1994). There are two polymorphic sites in 
this region, +121G/A and +93C/T. While the +121G/A substitution is rather without 
direct effect on apo(a) production rate (Brazier et al, 1999), the -93C/T 
polymorphism represents a functional change. The +93T allele is associated with 
60% decrease in apo(a) expression resulting from a reduction in translation due to the 
creation of a novel upstream ATG start site (Zysow et al., 1995). 
Several other polymorphisms have been described in the 5 'untranslated region 
(1,5 kb upstream from the transcription start site) of LPA gene. There are 
recognizable consensus sequenccs for nonspecific promotér elements (TATA, CAAT 
boxcs), hepatocyte Iranscription elements (HNF-la, CEIBP, LF-AI), and sequence 
motifs for interleukin 6 (IL-6) (Wade et al., 1993). This is consistent with findings 
that the Lp(a) particle probably contributes to wound healing processes. 
A polymorphic variant -772G/A was detected at this part of the promotér. It is not a 
functional change, howevcr a minor -772A allele was significantly associated 
(/X0,001) with lower mcan l.p(a) levels compared to the G variant in some studies 
(Brazier et al., 1999). Moreover such association persisted even after apo(a) isoform 
adjustment. 
The pcntanuclcotide repeat polymorphism (TTTTA„), referred as STR locus 
(Short Tandem Repeat), was deseribed at a distance of -1231 bp upstream from the 
transeription start site,. In Caucasians the number of repeats range from 7 to 11. 
Scveral studies have been referred to significant association of difTernt STR alleles 
and l.p(a) plasma levels (Kalina el a/.,2001; Holmer el al.,2003). This polymorphic 
locus was able to explain from 5 to 14,3% of the l.p(a) plasma levels variability 
independently of apo(a) isoform size (TrommsdorfTet al., 1995; Brazier el al., 1999). 
Such association is supposed to bc due to linkagc of certain STR alleles with a 
rcstricted range of K1PAIV type 2 repeats and with functional variants from the 
coding sequences and transeription regulátory regions. In adition the work by Negi el 
al. (2004) proposed its possible direct effect on LPA gene transeription as a negative 
transeription binding site. 
1.2.1.2. l.2.Enhancers 
An intensive search for additional regulátory sequences of LPA gene 
uncovercd two regions carrying properties of enhancers. Two different areas, 20 kb 
(DHIII enhancer) and 28 kb (DH1I enhancer) upstream of the transeription start site, 
stimulate the transeription in an orientation independent manner (Wade el al., 1997; 
Huby el al.,2003; Puckey a Knight,2003). Neither of those enhancers appear to bc 
cell type specific (Wade el al., 1997; Yange/ a/., 1998). It is possible that the 
chromatin structure at these sites is permissive for interaction with transeription 
factors only in differentiated hepatic tissue. It is consistent with the observed position 
of these enhancers within DNasel hypersensitive sites that are present only in 
hepatoma cell chromatin and absent in other cell types (Wade cl al., 1997). 
The DHII enhancer activity is colocalized to a 180 bp fragment and stimulates 
transription activity from the LPA gene promotér from 4 to 8 fold (Wade el al., 1997; 
Puckey a Knight,2002). Various members of the nuclear receptor family (PPARa. 
E-SR) were reported to bind the DHII enhancer binding elements, suggesting to 
mediate drug and hormone responsiveness (Puckey a Knight,2002). No sequence 
variability was detected in this enhancer. 
The DHIII enhancer activity was mapped to a 600 bp fragment that stimulates 
LPA gene expression from 10 to 15 fold (Wade el al., 1997). The region was revealed 
to be a part of LINK-1 retrotransposon, indicating regulation sequences of 
retrotransposons may alter the expression of nearby genes (Yang el al., 1998). Three 
base substitutions (1230A/G ; -1617C/A; -I712G/T) with a direct functional impact 
on enhancer activity were detected in this enhancer (Puckey and K.night,20003). 
1.2.1.2.2. Kringle sequences 
Only a few functional variants were discoverd in the coding sequence of LPA 
gene so far. In particular in kringlelV type 8 p.P52L substitution associated with 
lower mean Lp(a) levels and both carriers contained the STR allele with 11 repeats in 
their promotér (Ogorelkova et cr/.,2001). The p.T23P substitution is found in the same 
kringlelV type 8 and is correlated with lower risk of atherosclerosis development 
(Ogorelkova et a/.,2001). The sequence change p.M75T in kringlelV type 9 was 
linked to inereased Lp(a) levels and to higher risk of myocardial infaretion (Simó el 
o/.,2001). Finally a rare substitution p.W72R that has a direct effect on Lp(a) particle 
binding properties to extraeellular and cellular surfaces was detected in the kringlelV 
type 10 (Simó et a/.,2001). 
Null alleles are defined by absence of apo(a) isoforms from immunoblots 
which depends on the method sensitivity. Such null alleles exist over the whole 
spectrum of apo(a) isoform size but are more frequent within large apo(a) alleles 
(Gaw et al., 1994; Kraft etal., 1996). Only two transcript negative null alleles were 
detected so far. In the first exon of kringlelV type 8 a substitution 1G/A results in an 
alternative splice site activation and with truncated apo(a) protein (Ogorelkova et al., 
1999). The base change 61CYT resides in the repetitive kringlelV type 2 region and 
creates a termination codon (Parson et al.,2004). 
1.2.2.LIPOPROTEIN(a) PARTICLE 
1.2.2.1.Lipoprotein(a) structure 
Apolipoprotein(a) is secreted from the hepatocyte as a free protein in a closed 
conformation (Démant et al.,2001; Becker et al., 2003). Conformational status of apo 
(a) plays a significant role in determining the efficiency of covalent Lp(a) particle 
formation. The open conformation of apo(a) forms covalent Lp(a) particles more 
efficiently than closed form of the molecule (Becker et al., 2004). There is an inverse 
relationship between apo(a) isoform size and the efficiency of transition from closed 
to open apo(a) conformation. Lipoprotein(a) assembly takés pláce extracellularly as a 
two-step process in which initial noncovalent interactions between apo(a) and 
apoB-100 precede the formation of a single disulfide bond (Trieu a McConathy,1995; 
Gabel a Koschinsky, 1998). The noncovalent step is mediated by interactions between 
apo(a) kringlelV type 7-8 and amino-terminal lysině residues of apoB-100 (Brunner 
et al., 1993; Koschinsky et al., 1993). 
Some of the apo(a) kringle IV domains are characterized by the presence of 
lysine-binding pockets. The kringlelV types 5-8 each contain a weak lysine-binding 
site, while apo(a) kringlelV type 10 contains a stronger lysine-binding site that has 
been proposed to mediate the binding of apo(a)/Lp(a) to ligands such as fibrin (Scanu 
et al., 1993; Ernste/ al., 1995; Gabel et al., 1996). 
1.2.2.2. Plasma lipoprotein(a) levels 
Despite nearly exclusive genetic determination to a unique locus I.p(a) 
concentrations are highly variable among individuals in all populations studied so 
far (Kraft et al., 1996; Paultre et al.,2002). Plasma levels vary over a 1 000-fold, 
ranging from 0.1 to over 6x102 mg/dl. l.ipoprotein levels are much less affected by 
age, gender, weight and diet than other classes of lipoproteins and remain 
relatively stable throughout life (Boerwinkle et al., 1992; Boomsma et al., 1993; 
Wild et al.,1997; Foody et al.,2000). As an exception menopause is associated 
with an 10-30% increase in Lp(a) concentration (Jenner et al.. 1993; Wilmink et 
al.,2000). 
The apo(a) circulating in plasma is synthesized exclusively in the liver 
(Hobbs a White,1999). Differences in plasma levels of l.p(a) are determined by 
differenccs in the rate of production, and not degradation. Individuals with diverse 
Lp(a) levels possess the same catabolised fraction of Lp(a) particle (Rader et 
al., 1993; 1994). Multiple factors contribute to the characteristic rate of Lp(a) 
production. The limiting step is the amount of apo(a) secreted by hepatocytes. lt 
could be influenced by the LPA gene transcription rate, mRNA stability and by 
posttranslation modifícation. The critical event is the time spent by apo(a) 
molecules of diffrent length in the endoplasmic reticulum. Larger apo(a) isoforms 
are retained for a prolonged time and thus greater proportion of these isoforms is 
degraded by proteasomes. Thus the apo(a) gene size heterogeneity (KLPAIV type 2 
repetition) accounting for 40-60% of the Lp(a) level variance (Kraft et al.,] 992; 
Brazier et al., 1999). 
1.2.2.3.Pathophysiology of lipoprotein(a) 
Apo(a) is presnt in atherosclerotic but not normál vessel walls, which suggests 
that Lp(a) may play a role later in the atherosclerotic process, after lesions have 
developed. In the early plaque, most of the Lp(a) is located within endothelial celis 
(Jamieson et al., 1995). Lipoprotein(a) may get trapped in lesions by binding to 
components of the subendothelial matrix and cell surfaces (Beisiegel et al., 1990; 
McConathy a Trieu,l99l; d Angelo et ai,2005; Tsurupa et ai,2006). In more 
advanced lesions, thc apo(a) is prcdominantly situatcd cxlracellularly within the 
thickened intima (Jamicson et ai. 1995). I.ipoprotcin(a) appcars to accumulate 
prefercntially to LDL within lesions (Bcisicgcl el al., 1990; Lawn el al.. 1992). 
l.ocalization of l.p(a) to the Icsion will increase local cholesterol dcposition and may 
have other effects that promote lesion development (Grainger et ai, 1993; Buechler et 
al..2003; Sotiriou et al.,2006) 
Many of the potential atherogenic properties of Lp(a) can be attributed to 
apo(a) structural similarity with plasminogen and its inability to be modified to active 
protease and thus it posscsses strong antifibrinolytic character (Rouy et al., 1992; 
Palabrica et a/.,1995; Falco et a/.,1998). 
l.2.2.4.Physiological role of lipoprotein(a) 
1'crhaps the most plausible idea regarding a possible physiologieal role for 
Lp(a) is that it participates in wound healing (Hobbs a White,1999). Apolipoprotein 
(a) is present in lesions during thc early stagcs of healing, when fibrin clots encase 
the wound and the wound is infiltrated with inflammatory eells (Yano et al, 1997; 
Mooser et al.,2000). I.ipoprotein(a) clots the fibrous cap and is present within and 
surrounding thc endothelial eells of newly infiltrating blood vessels (Mooser et 
ai,2000). Aftcr thc cpithclium has regenerated the apo(a) moleeule is no more 
dctcctcd in thc healing lesion, suggesting an early role for Lp(a) particle in the 
healing process (Yano et ai, 1997). 
II .AIMS O F T H E S T U D Y 
• to sean thc variability in known iPA gene eontrol regions (promotér, DUII 
and DHIII enhancer) 
• to analyse thc association of found polymorphic variants with quintiles of 
different range of Lp(a) levels (after thc subjects were separated into quintiles 
and randomly chosen sample from cach quintile was derived) 
• to assign the ratc of litikagc disequilibrium (LD) between each pair of 
polymorphic sites 
• to investigate if certain compound (5-polymorphic) genotypes are associated 
with narrow range of l.p(a) levels (at least in part due to linkage with 
restricted range of apo(a) gene KLPAIV type 2 length variants) 
I I I . M A T E R I A L S A N D M E T H Q D S 
III.l.SUBJECTS 
Two groups of subjects were uscd in this study. The DNA of 263 subjccts 
froni unrelated Caucasian individuals from Czech population was obtained froni tlíc 
Institute of Biology and Medieal Geneties, 1" Faculty of Medicine, Charles 
University in Prague. These were apparently normál individuals from sereening 
projects and volunteers and wc used them as the population samplc. 
The study subjects vverc seleeted from the DNA pool comprising out-patients 
from the l.ipid Clinic of the 3rd Medieal Department, I" Faculty of Medicine and 
General Teaching Hospital, Charles University in Prague. Individuals with renal 
insufficicncy and endoerine disorders were exeluded from the study. DNA and l.p(a) 
levels were available for I 830 unrelated individuals, either healthy or with 
dyslipidemia 82 2% of these were users of hypolipidemic therapy with statin further 
in 30.4% of them in combination with fibrates. I'he subjects were separated into 
quintiles and randomly choscn samplc from cach quintile was then derived having the 
total number of 713 individuals. Isl quintile l.p(a) levels from 0 to 8 mg/dl (134 
subjects), 2nd quintile l,p(a) levels from 9 to 15 mg/dl (134 subjects), 3 ,dquintile l.p 
(a) levels from 16 to 24 mg/dl (120 subjects), 4,h quintile l.p(a) levels from 25 to 64 
nig/dl (146 subjects) and 5lh quintile Lp(a) levels from 65 to 335 mg/dl (179 
subjects). DNA from these individuals was analysed. The more detailed 
characteristics of cach quintile is in Table.3.1. 
The compound genotypes analyses were done on a restricted sample si/.e of 
664 individuals. In comparison with the previous part of the study we seleeted only 
130 subjccts from the 5lh quintile to have a comparable sample sizes for all quintiles 
T he study was approved with the ethics committee and all subjects were given 
informed consent 
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111.2.LP(a) CONCENTRATION 
Lipoprotein(a) conccntrations wcre measured using frozen scrum (-20°C). 
separated within two hours after vcnous blood collcction, by immuno l.EIA' l.p(a) 
method (Tcchnoclonc GmbH, Vicnna, Austria). We used internal control samples as 
wcII as control samples and standards providcd by the manufacturer during each 
assay. l.ipoprotein(a) levcls for the population samplc were not available. 
111.3.DNA ANALYSIS 
III.3.1. AMPLIFICATION REACTION 
DNA was isolated from fresh or frozen whole blood using a salting out 
method modified according to Miller el al. (1988). The promotér region and the DHI1 
and the DHIII enhancer sequences wcre ampliíicd. The 50 nl reaction mixture 
contained 120-250 ngof genomic DNA, 3.5 mM (promotér) or 2 mM (DHIl 
enhancer) MgCI2, 200 ng of each primer, O l mM ofeach dNTP, l% DMSO and 0.5 
unit of Taq DNA Polymerase (recombinant) in the buffer provided by the 
manufacturer (Fermentas, Vilnius, Lithuania). Amplification conditions were 96°C 
for 2 min as a denaturation step followed by 35 cycles of 30 sec at 94°C, 30 sec at 
62°C and 30 sec at 72°C, ending with 3 min at 70°C. The l 142-bp unique fragment 
containing the whole DHIII enhancer sequence was produced according to Puckey 
and Knight (2003). As the DHIII core enhancer region is 600 bp long, wc divided it in 
two separatc amplified sequences with a 39-bp overlap. The first DHIIIA fragment is 
486 bp long and the second DHIIIB fragment is 243 bp long. The 50 jj' amplification 
reaction mixture for both fragments contained I (jl o f the l 142-bp PCR product as a 
template, 1.5 mM MgCI2, 200 ng of each primer, O l mM of each dNTP and 0.5 unit 
of Taq DNA Polymerase (recombinant) in the buffer provided by the manufacturer 
(Fermentas). Amplification conditions for both DHIII fragments were 96°C for 2 min 
as a denaturation step followed by 35 cycles of 30 sec at 94°C, 30 sec at 68°C and 
Materials and methods 
Table.3.2. 
Primer sequences used to amplify l.PA gene transcription regulátory regions and to prepare 
the DGGE artificial positive Controls 
primer name primer sequence T„, °C amplicon size 
promotorl-' 5 tatgttccattttgggactgg' 60 346 bp 
promotorR1 5 gatgaaggtctaggggtgagg 1 60 
promotorMut2 5 gatgaaggtctaggggtgagggaaggagtaaggatac 1 
DH1IF 5 tagcttttctgtgcatcggtctc ' 63 266 bp 
DHIIR1 atattgggggttcaggccac 1 63 
DHIlMut2 atattgggggttcaggccaccactagcgga' -
DHIIIAF 5 ctgctcaggggtcaggggtc 1 67 486 bp 
DM111AR' ctcccacccgaatactgcgc ' 67 
DHillAMut2 ctcccacccgaatactgcgcttttccgacaggct 1 -
DHI1IBF1 tccgagccaggtgcgggata ' 70 243 bp 
DHI1IBR 5 cgcccgccactgtgcgccagccgaagc' 72 
DHIlIBMut2 tccgagccaggtgcgggatataaactcccggcgca 1 -
S T R F ( F A M ) s cagctactagggaggctgga ' 60 164-184 bp 
STRR s ttcatttgcggaaagattga 5 59 
1 GC-clamped primer. sequence of the clamp: 5 gcgcccgcggccgcccggcccgcccgcccgcgccgccccg ' 
2 mutation primer; t the site of introduced mutation 
20 sec at 72°C, ending with 3 min at 70°C. All primers used to amplify LPA gene 
regulátory sequences are summarized in Table.3.2. 
The pentanucleotide microsatelite from the distal promotér was amplified 
using one fluorescently (FAM) labelled primer (Table.3.2 ). The 25 ml amplification 
mixture contained 120-250 ng of genomic DNA, 2.5 mM MgCI2, 200 ng ofeach 
primer, 0.1 mM of each dNTP and 0.5 unit of Taq DNA Polymerase (recombinant) in 
the buffer provided by the manufacturer (Fermentas). Amplification conditions were 
96°C for 2 min as a denaturation step followed by 25 cycles of 30 sec at 94°C, 30 sec 
at 62°C and 20 sec at 72°C, ending with 3 min at 70°C. The amplified product size 
rangcd from 164 bp (7 repeats) to 184 bp (11 repcats). The exact length was 
measured by fragmentation analysis conducted on ABI PRISM 310 Ocnetic Analyser 
(Applied Biosystcms, Poster City, CA, USA). 
The 263 subjects of the population samplc werc directly genotyped for six 
selected polymorphic sites from the regulátory regions of LPA gene (+12IG/A; 
+93C/T; -1231 TTTTA„; -I7I2GA1'; -I617C/A; -1230A/G). The promotér region, 
DHIIIA, and DHIIIB enhancer fragmcnts were amplificd and the TTTTA„ repetition 
was genotyped according to above-mentioned protocols. All RFLP assays were 
carried out in 10 ml reaction mixtures using 5 unita of respective restriction 
enzyme and 5 ml of relevant amplified fragment. The respective fragments were 
restrictcd by ///j>>-I8811i (NF.B, Inc., lpswich, United Kingdom), HpyCW4IV (NEB), 
and DpnU (NEB) enzymes to get the +121G/A , +93C/T , and -1230G/A 
polymorphisms, respectively. 
Population frequcncics of two variants, -I712G/T and -1617C/A, were 
evaluated by allele spccific amplification. Both 25 ni reaction mixtures contained 
120-250 ng of genomic DNA, 1.0 mM MgCI2, 0.08 mM ofeach dNTP, and 0.3 unit 
of Taq DNA Polymerase (recombinant) in the bulTer provided by the manufacturcr 
(Fermentas, Vilnius, Lithuania). The -I712G/T variant was detccted using 70 ng of 
allele-spccific l712alA primer, and 50 ngof l712com primer. As for the -1617C/A 
polymorphism, the appropriate amplification fragments were produced using 
combination of 70 ng of 1617alA primer, 90 ng of 1617alC primer, and 50 ng of 
1617com primer in each amplification reaction. All primers used for allele specific 
amplification are summarized in Table.3.3. Amplification conditions were 96°C for 
2 min as a denaturation step followed by 35 cycles of 30 sec at 94°C, 20 sec at 58°C 
(-1712GfI) or at 50°C (-1617C/A), and 20 sec at 72°C, ending with 3 min at 70'C. 
Products of amplification rcactions were then subjected to 2% agarosc gel 
electrophoresis and visualiz.ed by following ethidium bromide staining. The -I712T 
allele carriers were subsequently proved by sequencing reaction of DHIIIB fragment 
on ABI PR1SM 310 Genctic Analyzer (Applied Biosystems, Foster City, CA, USA). 
Table.3.3. 
Primer sequences used to detect-I712GAI , and -1617C/A polymorphisms in the LPA gene 
DHIII enhancer region using allele-specifíc amplification 
primer name primer sequence T m ° C amplicon size 
l712alA' 5 gccagccgaatca tggt ' 56 181 bp 
17!2com ' gtgcgggalataaactcc ' 55 
1617alC* s acctggaaaatcgagtc ' 50 160 bp 
1617al A 1 2 ' "Igcgaaacggaatgcgltaaalgclaaacclgga 50 188 bp 
aaatcgagta ' 
1617com 5 ccttgcagtttgatctc ' 50 
1 allele specific primer; t is the site of introduced change 
! atgcg the non complementary part of primer 
II1.3.2.DGGE ANALYSIS 
To find unknown changes, the DGGE analysis of amplified fragments was 
used (BioRad Laboratories Inc., Hercules, CA, USA; lloefer, Amersham Biosciences 
Corp., San Francisco, CA, USA) combined with sequencing. Morcover, a spccific 
mutation primer was designed for each analysed fragment to obtain artificial positive 
controls (Table.3.2 ). The change was introduced to a domain with the highest 
melting temperature in the vicinity of GC-clamped primer. lt is supposed to be the 
site with the most difficult substitution detection. Mutated PCR products were used in 
the course of condition optimisation and as positive controls during each run. 
Heteroduplexes were formed by denaturation of amplified products for 5 min at 
96°C, followed by ineubation for one hour at annealing temperature. The DGGE 
conditions for the minimal promotér fragment were 6% PAD gel, 16 cm long with, 
denaturing gradient 20-80%, run for 8 hours at 150 V and 60°C. The DH1I amplicon 
was run for 8 hours at 150 V and 60°C on 8% PAD gel, 10 cm long with denaturing 
gradient 30-80%. The DHIIIA fragment was analysed in 6% PAD gel, 16 cm long 
with denaturing gradient 30-90%, and run for 16 hours at 150 V and 60°C. 
The conditions for the DHIIIB fragment were 8% PAD gel, 10 cm long with 
dcnaturing gradient 40-80%, run for 2 5 hours at 150 V and 60°C. All novel SNPs 
wcrc verificd by two different methods (sequencing, DGGE) and in two independent 
PCR reactions and DGGE runs. 
III.4.STATISTICAL ANALYSIS 
Allele frequencies were obtained by allcle counting and standard errors were 
assigned. Kach polymorphic locus was tested for significant deviation of genotype 
distributions from Hardy-Weinberg equilibrium using thc x2 test (p<0.05; ld.f.) for 
di-allclic sites and thc exact test for the STR locus. Significance of allele frequencies 
diffcrcnces between quintiles was evaluated using the x2 test. Non-random 
association between cach pair of sites was mcasured by the standardized 
disequilibrium statistic (A) (Chakravarti et al., 1984), after haplotypc frequencies were 
estimated by maximum likelihood proceduře. The statistical significance o fA statistic 
was tested applying a x2 test of independcncc. Association of compound genotypes 
w ith I.p(a) levels was evaluated using the l-way ANOVA test (STATISTICA, 
version 7.1). Haplotypcs were reconstructcd using Ilaplovicw (version 32.2) 
programme (www.broad.niit.edu/mpg/haploview ) (Barrctt et al.,2005). 
IV.RESULTS 
IV.l.POLYMORPHISMS IN THE PROMOTÉR 
The 346 bp fragment harbouring sequcnce of the promotér was analysed 
Except for the two previously deseribed polymorphisms, +121 G/A; +93C/T, we havc 
observed threc novel substitutions +62T/C (8 subjects); -70C/T (1 subject); -93G/A 
(I subject). The two latter variants were present only once in the same individual 
suggesting the cis position. Allele frequencies of the two polymorphic sites are 
summarized in Table.4.1. The genotype frequencies distribution for both promotér 
polymorphic sites was in Hardy-Weinberg equilibrium in all quintiles. There is a 
bimodal distribution of the +121A allele aeross quintiles having the highest 
frequency in the 2"d and 5lh quintile, that was significantly (p=0.020) inereased 
comparing to the 4,h quintile. The +93T allele frcquency was comparable in all 
quintiles with an exception of the 5lh quintile where was thc frequency significantly 
(p=0.005) deereased. The +62T/C' variant was found in four carriers from the 3'd 
quintile, in thrce carriers from the 4lh quintile and in onc carrier from thc 5lh quintile 
[mean l.p(a) level in carriers 33.5 ± 5.3 mg/dl], All carriers of the +62C variant, 
except one with the 9-STR allcle, possess thc STR allele with 10 repetitions and 
+ 121 G/O and +93C/C promotér genotypes. 
The pentanucleotidc microsatelite at the distal promotér of LPA gene was 
amplified. The PCR product varicd in size and cover from 7 to 11 TTTTA repeats. 
Allele frequencies of the STR locus in each quintile are summarized in Table.4.1. 
The most common allele had 8 repeats. There was a significantly (p=0.003) higher 
joint frequency of short alleles (7- and 8- repeats) in the 5lh quintile comparing to 
other quintiles. The 9-STR allele frequency was significantly (p=0.030) deereased in 
the 5,h quintile comparing to other quintiles. The STR allele with 10 repeats was 
underrepresented in quintiles of both extremes reaching the statistical significance 
when compared to the 2nd and 3rd quintile (p=0.020 for the 5,h quintile and p=0.040 
for the 1" quintile). Thc highest frequency of the 11-repeat allele was observed in 
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quintile including two homozygotes that were not detected in other quintiles and in 
the ISlquinitile which affected the Hardy-Weinbcrg equilibrium. The STR genotype 
frequencies distribution in other quintiles was in Hardy-Weinberg equilibrium. The 
difTerence in 1 l-repeat allclc frequency in the I" and in the 2"d quintile comparing to 
the 5lh quintile was statistically significant (p=0.002 and p=0.017. respcctively). 
Group of 263 subjects, considered as the population samplc, was gcnotyped 
four five selected single nucleotide polymorphism and one S I R locus from the LPA 
gene transcription regulátory scquences. Ascertained allelic frequencies of these 
polymorphic sites in the population samplc were as follows: +121G/A (0.814/0.186 ± 
0.017): +93C/T (0.882/0.118 ± 0.014); -1231 TTTTAn STR-7 (0.006 ± 0.003), STR-8 
(0.705 ± 0.020), STR-9 (0.120 ± 0.014), STR-10 (0.150 ± 0.016), S I R-11 (0.019 ± 
0.006). -1712 G>T (0.996/0.004 ± 0.003). The genotype frequencies distribution for 
all polymorphic sites was in Hardy-Weinberg equilibrium. 
IV.2.POLYMORPHISMS IN THE ENHANCERS 
The 266 bp fragment encompassing the entire DHI1 enhancer was almost fully 
conserved with only two mutations detected, -213C/T and -114G/T, each of them 
observed only once in individuals from the 5lh and 2nd quintile, respcctively. Neither 
of them reside DNase-I footprints located close to them (Puckey and Knight,2003; 
Wade et al., 1997). 
The 600 bp core DH1II enhancer was divided into two separately analysed 
PCR products with a short overlap. We detected three already reported variants; 
-1712G/T (2 subjects); -1617C/A; -1230A/G, and eleven novel rare base 
substitutions: -1711C/T (1 subject);-1586G/A (1 subject);-1557A/G (4 subjects); 
-1540G/A (1 subject); -1521 G/A (1 subject);-I408C/T (1 subject);-1357C/T (1 
subject); -1301 CAI' (1 subject); -1274G/A (1 subject); -1253GM' (2 subjects); 
-12I9G/A (I subject). Allele frequencies for DHIII enhancer polymorphic sites in 
quintiles are summarized in Table.4.1. The genotype frequencies distribution for 
polymorphic sites was in Hardy-Weinberg equilibrium in all quintiles. The -I617A 
allele frequency seems to have a bimodal distribution across quintiles reaching the 
pcak in the 3,d and 5"1 quintile, in the latter one being significantly (p=0.013) 
increased comparing to the 1", 2°d and 4lh quintile. The highest frequency of the -
1230G allele was observed in the 2nd quintile that was significantly (p=0.014) 
different from the frequency in the 4lh and 5lh quintile. 
Ascertained allelic frequencies of these polymorphic sites in the population 
samplc were as follows: -I617C/A (0.856/0.144 ± 0.015); -1230A/G (0.532/0.468 ± 
0.022). 
IV.3.LINKAGE DISEQUILIBRIUM 
Linkagc disequilibrium was measured in the population samplc for each pair 
of polymorphic sites in the promotér (+12IG/A; +93C/T; STR) and for all pairs 
between these sites and two polymorphic DHIII enhancer variants (-1617C/A; 
-I230A/G). Wc considered three alleles for the STR locus. The allele with 7- and 
8- repeats were designated as S (short), the allele with 9- repeats as 9, and the alleles 
with 10- and 11- repeats as L (long). The linkage disequilibrium for each STR allele 
(S, 9, L allele) was calculated as for di-allelic locus using the relevant allele 
frequency opposing to all other STR alleles pooled together. The -1712T variant was 
too rare to conduct l.D calculation and was thus excluded from consequent analyses. 
Values of standardized disequilibrium statistics (A) are given in Table.4.2. 
IV.4.COMPOUND GENOTYPES 
We have detected 91 different 5-polymorphic (5-pol) genotypes (+121G/A; 
+93C/T; -1231 TTTTA„; -1617C/A; -1230A/G) in the outpatient group. Only fifteen 
of them have overall quintile frequency above 0.01. These fifteen genotypes have a 
combined frequency of 0.689 in the population sample. Frequencies and relevant 
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Table. 4.3. 
The most common 5-pol compound genotypes of LPA gene regulátory sequences, frequency 
in quintiles, relevant mcan l.p(a) levels i standard deviation (SD). and population frcquency 
Geno types ' ! Quintile 
frequency J 
Mean l.p(a)(mg/dl)4 Population 
i SD frequency 
GGCC88CCAA 0.190 4 8 6 ±51 .4 0 183 
GACC88CCAG 0 164 32 9 ± 42.0 0 133 
GGCC8I0CAAG 0 065 47 6 i 42.8 0.087 
GGCT89CCAG 0.075 27.3 i 31.6 0.065 
GGCC88CCAG 0.032 35.0 i 33.0 0,061 
GGCC89CCAA 0.023 21 6 ± 33.0 0.030 
AACC88CCGG 0.030 23.4 i 35,8 0.027 
GACT89CCGG 0.015 24.0 ± 37.1 0.027 
GGCT8I0CCAG 0.017 12 8 ± 17.3 0.019 
GGCT89CCAA 0.020 50.5 ± 56.5 0.015 
GACC7/88CAAG 0.032 1470 ± 49.1 0.011 
GGCC7/88CAAG 0.015 29.8 1 36.7 0.011 
GGCT810CCAA 0 017 30 6 ± 42.4 0 008 
GGCT910CAGG 0 015 23.3 i 17.0 0.008 
GACC89CCAG 0.014 116 ± 15.4 0.004 
' genotypes are designed from the 3 - end to the 5 - end o f t h e apo(a) gene locus 
1 7 /8 indlcate that compound genotypes carrying both the 7 allele and the X allele in 
combination with the 8 allele of the STR locus werc included 
3 compound genotype frequency in all quintiles (outpatient sample group) 
' mean l.p(a) level and standard deviation associated with compound genotype in all quintiles 
mcan l.p(a) levels of the ftftcen 5-poi genotypes in the outpatient group and 
frequencies in the population group are summarized in Tablc.4.3. There is a 
statistically significant association of mean I.p(a) levels with compound 5-pol 
genotypes (d.f.14/464; F=10.54; p<0.000l). 
Particularly, onc genotype GACC7/88CAAG was seen 20 times in the 5,h 
quintile [mean Lp(a) level in carricrs 147.0 ±49.1 mg/dl] and was not present in other 
quintiles and only three times in the population group. The genotype consists from 
the most common haplotype GC8CA and from a rare AC7/8AG haplotype. The 
AC7/8AG haplotype carriers were significantly (P<0.0001) associated with l.p(a) 
levels over 65 mg/dl. Several other 5-pol genotypes were also associated with a 
narrow range of Lp(a) levels. In detail, the GACC89CCAG (11.6 ±15.4 mg/dl), the 
GGCT810CCAG (12.8 ±17.3 mg/dl), and the GGCT910CAGG (23.3 ±17 0 mg/dl) 
genotype carriers were linked to low and middle mcan l.p(a) concentrations. 
However, all these 5-pol genotypes were quitc rare in the population group 
V.DISCUSSION 
Microvariants LPA gene regulátory sequences are supposed to contribute to 
the high variability of l,p(a) plasma concentrations. We separated the subjects into 
quintiles to detect the distribution of polymorphic variants across the range of Lp(a) 
levels. The so called minimal promotér of LPA gene houses essential transeriptional 
and hcpatic tissue spccific regulátory elements (Wade el al., 1994). In our study we 
detected two reported polymorphisms (+121 G/A; +93C/T) and threc novel rarc 
substitutions. The role of + I2IG/A substitution is somehow ambiguous. Study by 
Suzuki el al. (1997) had indicatcd its potentially positive role in LPA transeription 
what was not clearly reproduced by others (Wu and l.ee,2003). The +121A allele was 
associatcd with elevated l.p(a) levels when compared to the major G allele in scvcral 
studies (Puckcy el al., 1997; Prins el al., 1999) but contrary data are also available 
(Brazier e/a/ . , 1999). It could bc the linkage to other functional variants what can 
explain such heterogeneous data. This is supported by the strong linkage 
disequilibrium between the +121A allele and the DHIII -1230G variant as well as 
with short S I R allelcs (7- and 8-repcats) observed in our study. The +121A allele 
was also reported to be associatcd rather with middle si/.ed (26-35 KLPA1V2 repeats) 
and large apo(a) isoforms (Puckcy el al.. 1997). 
Lower frequency of the +93 1' promotér variant in the 5,h quintile is consistent 
with its previously deseribed linkage disequilibrium with 9-STR allele and its direct 
negative effect on apo(a) translation efficiency (Zysow el al.. 1995). The +931' variant 
was probably evolved on chromosome with 9 repeats and expanded to the other STR 
allelcs during the locus evolution. The 9-STR allele was reported to be associatcd 
with apo(a) middle sized isoforms, KLPAIV2 24-34 repeats (Mooser et al., 1995). The 
three novel promotér variants do not reside in known transeription factors binding 
sites and are too rarc to reveal a significant association with Lp(a) concentration. 
However, the +62C variant was only found among individuals with Lp(a) levels over 
16 mg/dl. 
Sevcral studies have reported a correlation between the allcles of S I R locus 
at a distal LPA gene promotér and plasma l.p(a) concentrations (Brazier el al.. 1999; 
Kalina el al..2001). The correlation was independent of apo(a) size isoforms and it 
accounted for 5 to 14 % of L.p(a) level variation (Brazier e řa / ,1999; Trommsdorff el 
al., 1995). Our findings are consistent with these data. It is supposed to be due to the 
linkage disequilibrium of different S I R allelcs to distinct range of apo(a) isoforms 
and to other functional changes influencing apo(a) production rate. Morcovcr, recent 
work by Ncgi el al. (2004) proposed its possible dircct effect as a transeription 
factor-binding sitc. 
There was a limited incidence of the 1 l-repeat allele on short apo(a) isoforms 
in previous studies (15-24 repetic KLPA1V2) (Mooser el al.. 1995). However, this S'1'R 
variant was very rare in the 4"1 and 5'h quintile in our study, having the highest 
frequency on the oppositc end of Lp(a) range. Ogorclkova el al. (2001) proposed a 
linkage between the P521. polymorphism and the 11-repcat allele. The P521. 
substitution in LPA gene coding region (KLpAlIV8) may negatively modify protein 
folding. Deviation from the llardy-Weinberg cquilibrium observed in the ls ' quintile 
was created bccausc of selection eriterion, sincc genotypes that are responsible for 
extremely low Lp(a) levels are expected to be overrepresented in this quintile. 
An intensive search for additional LPA gene regulátory sequences uncovcred 
two upstream regions having properties of enhancers (Wade el al.. 1997; Huby el 
al..2003; Puckey and Knight,2003). We investigated these sites for presence of 
common variants. The previous in vitro mutation analyses revealed sensitiveness of 
DHII enhancer activity to mutations (Wade el al., 1997). However, sequence of this 
enhancer exhibited a strong conservation and showed no common variability in our 
study. The DHII enhancer is the likely site of estrogen and other hormones and drugs 
operation (Puckey and Knight,2002). Our rcsults indicate there is no common 
population variability in responsiveness to these molecules mediated by this LPA 
gene regulátory element. On the other hand, the DHIII enhancer possesses much 
higher diversity and could, at least to some extent, explain the high variability of 
l.p(a) levels. Hxcept for three previously reported changes (Puckey and Knight,2003), 
-I7I2G/T; -16I7C/A; -1230A/G, we have detected eleven novel variants. 
I'he -1586G/A; -1408C/T; -1253G/T and -I219G/A base substitutions residc in 
distinet DNase-l protected sequences (Wade et al., 1997). The second one altered the 
eore Ets transeription faetor recognition element with significant effect on enhaneer 
aetivity in previously reported mutagenesis attempts (Yang et al., 1998). Nevertheless, 
all novel variants are very rare, playing no significant role in Lp(a) plasma variability 
at a population level 
Selected polymorphic sites were genotyped in thc population based sample 
group. Allele frequencies of these variants were comparablc to frequencies in other 
Caucasian populations (Trommsdorff el al., 1995; Puckey el al., 1997; Kfaft el 
al., 1998 ) or to frequencies in thc Puckeys study (Puckey and Knight,2003) with an 
exccption of thc -1712T variant that was quite rare in our population sample group. 
Several studics have pointed out the low recombination rate in the whole LPA 
gene region and high linkage between observed polymorphic sites (Boerwinkle et 
al., 1992; Puckcy el al, 1997; Puckey and Knight,2003 ). Wc have calculated the rate 
ofgenetic linkage between each pairof polymorphic sites involved in our study (with 
an exclusion of the -1712GH~ base substitution). Our results confirmed the strong 
linkage disequilibrium between the 9-STR allele and the +93T variant detcctcd also 
by others (Puckey el al., 1997; Kfaft el al., 1998). There was a persistent strong 
linkage cvcn between regulátory sites more than 20 kb far-away. 
In contrast with the persistent LD throughout the LPA locus, all major 5-pol 
compound genotypes were distributed in a broad range of lipoprotein levels. Only 
several rare 5-pol genotypes were restricted to a narrow range of Lp(a) 
concentrations. Each polymorphic site evolved as an independent event during the 
LPA gene locus evolution on certain apo(a) isoform background. Unequal sister 
chromatid exchange and gene conversion could be possiblc mcchanisnis of a new 
apo(a) isoform evolvement and redistribution of polymorphic sites without disrupting 
linkage disequilibrium. Thus, major 5-pol compound genotypes are not associatcd 
with restricted range of l.p(a) plasma levels. 
VI.CONCLUSION 
lncreased levels of l.p(a) are supposed to be an independent risk factor for 
atherosclerosis. Apolipoprotein(a) determines structural and functional characteristics 
of the Lp(a) particle. The Lp(a) concentration is almost entircly genetically 
determined with an exclusive linkage to a unique locus, thc gene for apo(a), so called 
LPA locus. Nevertheless I.p(a) concentrations varies widely between individuals in 
all populations studicd so far. There is a LPA gene size heterogeneity (Ki.PAIV type 2 
repetition) accounting for 40-60% of thc variance. Some of thc variance could be 
additionally related to polymorphic sites either in the coding scquence or in 
transeription regulátory regions of LPA gene. 
Only a few functional variants were discovcred in a coding part of LPA gene so 
far. Moreover LPA gene transeription regulátory regions we had analysed, have not 
been revealed to be extremely polymorphic. Howcver significant linkage 
disequilibrium was detected even between polymorphic sites from far regulátory 
sequences. In contrast with thc persistent gcnetic linkage all major 5-polymorphic 
compound genotypes were distributed in a broad range of Lp(a) levels. 
Considering the low recombination rate that tends to preserve the anccstral 
chromosome segment composition we suggest the unequal sister chromatid exchangc 
and gene conversion as possiblc mechanisms of a new apo(a) isoform evolvement 
and redistribution of polymorphic sites without disrupting linkage disequilibrium. 
Thus, combined effect of all polymorphic sites from the whole LPA gene locus, 
including the gene length polymorphism, should be considercd when dealing with 
high population variability of Ep(a) levels. 
Besides, minor impact of other locuses and modulation by non-genetic factors 
should be considered. 
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